What is the TECH stock price?

Bio-Techne Corp. (TECH) latest quote: $72.67, as of 10/27/26 1:51 PM ET. Prices on Cylvex may be delayed.

How many analyst price targets for TECH were reached?

9 of 16 published price targets for TECH were reached within 12 months (56% reached); 1 is still open. Counts only — firm names and target values are shown to signed-in members.

How many firms publish price targets or ratings on TECH?

11 firms have published price targets or ratings on TECH that Cylvex tracks. Counts only — firm names and target values are shown to signed-in members.

Is this investment advice?

No. Cylvex is an educational and informational platform; nothing on this page is investment, financial or trading advice. Past analyst targets do not predict future results.

TECH

Bio-Techne Corp. · NASDAQ

$72.67USDCS band Mixed

↓ $0.03 (0.03%) Today

As of Oct 27, 1:51 PM ET · May be delayed

Daily prices

Mkt Cap

$11.4B

Volume

52W High

$72.72

52W Low

$43.20

PE Ratio

62.7

Avg Vol

3.1M

As of 10/26/26

Div Yield

0.44%

Beta

0.74

As of 10/26/26

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Sentiment

No sentiment yet

At least 5 tagged posts are needed.

How do you feel about TECH?

Latest news

News ›

Zacks Investment Research9/30/26

INCY or TECH: Which Is the Better Value Stock Right Now?

A comparison of two medical-biomedical and genetics stocks reveals that Incyte (INCY) is the more attractive value investment option. INCY holds a Zacks Rank #2 (Buy) with improving earnings outlook and a Value grade of B, while Techne (TECH) has a Zacks Rank #3 (Hold) and Value grade of D. INCY's lower PEG ratio (2.67 vs 7.53) and P/B ratio (3.94 vs 5.38) suggest better valuation metrics.

INCY

Headlines link to the publisher. Not investment advice.

Board · 0 threads

Open board ›

No threads yet

Cylvex posts are automated counts of published analyst actions, not opinions. Not investment advice.